Table 1.
Randomized subject baseline characteristics.
| Population | Treatment Group | p-value | |
|---|---|---|---|
| Original Study | DFMO (n=144) | Placebo (n=147) | |
| Age(y) | 61.6 ± 10.7 | 60.2 ± 11.0 | |
| Gender | |||
| Female | 57 (39.6%) | 59 (40.1%) | |
| Male | 87 (60.4%) | 88 (59.9%) | |
| Race | |||
| White | 144 (99.3%) | 147 (100%) | |
| Hispanic | 1 (0.7%) | 0 (0%) | |
| Body Surface Area (m2) | 1.94 ± 0.23 | 1.99 ± 0.23 | |
| Prior NMSC | 4.2 ± 7.7 | 4.9 ± 5.7 | P=0.10 |
| Prior Tumor Rate | 2.3 ± 3.3 | 2.1 ± 3.4 | P=0.08 |
| Retrospective Study | DFMO (n=108) | Placebo (n=101) | |
| Age(y) | 61.4 ± 10.9 | 60.4 ± 11.0 | |
| Gender | |||
| Female | 43 (39.8%) | 46 (45.5%) | |
| Male | 65 (60.2%) | 55 (54.5%) | |
| Race | |||
| White | 107 (99.5%) | 101 (100%) | |
| Hispanic | 1 (0.5%) | 0 (0%) | |
| Body Surface Area (m2) | 1.94 ± 0.23 | 1.96 ± 0.23 | |
| Prior NMSC | 3.2 ± 3.0 | 5.5 ± 6.3 | P=0.01 |
| Prior Tumor Rate | 2.5 ± 3.5 | 2.4 ± 3.9 | P=0.57 |
Note: for continuous data, mean values ± SD are presented. For categorical data, N (%) are presented. Prior tumor rate is defined as the number of prior skin cancers divided by the time from initial diagnosis to randomization.